Fiagon AG Medical Technologies is now part of Intersect ENT – Click here to learn more about our navigation offering

Investor Relations

News

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Announces Specialty Pharmacy Partnership Agreement with AllianceRx Walgreens Prime to Distribute SINUVA® Sinus Implant View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2020 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 4, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the second quarter ended June 30, 2020 .
View HTML
Toggle Summary Intersect ENT to Report Second Quarter 2020 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 22, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it will release second quarter 2020 financial results on August 4, 2020 .
View HTML
Toggle Summary Intersect ENT Announces Independent Analysis in UK Confirming Cost Effectiveness of PROPEL® Steroid Releasing Sinus Implant Following Sinus Surgery for Chronic Sinusitis
Toggle Summary CMS Approves SINUVA® Sinus Implant for Reimbursement with New C‐Code and Pass‐Through Payment Status
Toggle Summary Intersect ENT to Present at the William Blair 40th Annual Growth Stock Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--May 26, 2020-- Intersect ENT, Inc. (Nasdaq: XENT ), today announced that management will participate in a virtual fireside chat at the William Blair 40 th Annual Growth Stock Conference . The fireside chat will take place on Thursday, June 11, 2020 at 8:00 a.m.
View HTML
Toggle Summary Intersect ENT Reports First Quarter 2020 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--May 11, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the first quarter ended March 31, 2020 .
View HTML
Toggle Summary Intersect ENT Announces $65 Million Convertible Notes Investment from Deerfield Management
MENLO PARK, Calif. --(BUSINESS WIRE)--May 11, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it has closed a $65 million convertible notes financing with a fund managed by Deerfield Management
View HTML
Toggle Summary Intersect ENT Reschedules Time of First Quarter 2020 Financial Results Conference Call to 4:30 P.M. ET on May 11, 2020
MENLO PARK, Calif. --(BUSINESS WIRE)--May 8, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced the Company has rescheduled a conference call to discuss its first quarter 2020 financial results to 4:30
View HTML
Toggle Summary Intersect ENT to Present at the 2020 Bank of America Merrill Lynch Global Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--May 7, 2020-- Intersect ENT, Inc. (Nasdaq: XENT ), today announced that management will participate in a virtual fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference . The fireside chat will take place on Thursday, May 14, 2020 at
View HTML